Abstract: Objective To study the clinical efficacy of modified Hype-CVAD/MA regimen in children lymphoblastic lymphoma (LBL) patients. Methods Eleven children LBL cases accepted modified Hype-CVAD/MA regimen were divided into group A and B. Results Eleven cases totally received 41 cycles of regimen A，40 cycles of regimen B and 34 cycles of intrathecal injection.The adverse reactions of chemotherapy included bone marrow inhibition 100% (81/81)，gastrointestinal reaction 39.5% (32/81)，bacterial infections 33.3% (27/81)，stomatitis 30.8% (25/81)，shallow phlebitis 28.3% (23/81)，liver damage14.8% (12/81)，but all of those didn′t affect chemotherapy process.1~2 cycles later，the complete remission (CR) rate was 27.3% (3/11)，partly remission (PR) 45.4% (5/11) and disease stable (SD) 27.3% (3/11);after 3~4 cycles，CR was 72.2% (8/11)，PR 18.2% (2/11) and SD 9.1% (1/11);6~8 cycles later，CR was 81.8 % (9/11)，PR 9.1% (1/11)，and progressive disease (PD) 9.1% (1/11).The total remission rate was 90.9%.After median 19 months (average 23.6 ± 15.4 months) follow-up，disease-free survival had 9 cases，1 case survival with tumor and 1 case death. Conclusion The efficacy of modified Hype-CVAD/MA regimen as a initial treatment in children LBL was favourable，and adverse reactions were tolerable.